Skip to main content

Clinical Trial Results

Primary Navigation

Home
Slide Library
This Week in Medicine®
Past Videos
About
Contact

Dr. Rohan Khera and Dr. C. Michael Gibson discuss: Artificial Intelligence in cardiovascular care

Search for:
Search archived content (2018 and prior)

June 19, 2025

Disclosures: Sponsored by BridgeBio Pharma, Inc

Article Navigation

Dr. Daniel Judge and Dr. C. Michael Gibson discuss data presented at ACC 2025: Primary Endpoint Efficacy Results in The Attribute-CM Study: Pre-Specified Sensitivity Analyses Addressed Tafamidis Use. Sponsored by BridgeBio Pharma, Inc

Dr. Daniel Judge and Dr. C. Michael Gibson discuss data presented at ACC 2025: In Participants Treated with Acoramidis, Addition of Concomitant Tafamidis Did Not Further Increase Serum TTR Levels sponsored by BridgeBio Pharma, Inc.

Footer Navigation

LinkedIn
Twitter
Email

Search for:
Search archived content (2018 and prior)